134 related articles for article (PubMed ID: 19488725)
1. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
Gu F; Langer R; Farokhzad OC
Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Wu M; Wang Y; Wang Y; Zhang M; Luo Y; Tang J; Wang Z; Wang D; Hao L; Wang Z
Int J Nanomedicine; 2017; 12():5313-5330. PubMed ID: 28794625
[TBL] [Abstract][Full Text] [Related]
3. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Farokhzad OC; Cheng J; Teply BA; Sherifi I; Jon S; Kantoff PW; Richie JP; Langer R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6315-20. PubMed ID: 16606824
[TBL] [Abstract][Full Text] [Related]
4. Second-generation aptamer-conjugated PSMA-targeted delivery system for prostate cancer therapy.
Wu X; Ding B; Gao J; Wang H; Fan W; Wang X; Zhang W; Wang X; Ye L; Zhang M; Ding X; Liu J; Zhu Q; Gao S
Int J Nanomedicine; 2011; 6():1747-56. PubMed ID: 21980237
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles.
Dhar S; Gu FX; Langer R; Farokhzad OC; Lippard SJ
Proc Natl Acad Sci U S A; 2008 Nov; 105(45):17356-61. PubMed ID: 18978032
[TBL] [Abstract][Full Text] [Related]
6. Plumbagin-loaded aptamer-targeted poly D,L-lactic-co-glycolic acid-b-polyethylene glycol nanoparticles for prostate cancer therapy.
Pan M; Li W; Yang J; Li Z; Zhao J; Xiao Y; Xing Y; Zhang X; Ju W
Medicine (Baltimore); 2017 Jul; 96(30):e7405. PubMed ID: 28746182
[TBL] [Abstract][Full Text] [Related]
7. A RNA-DNA Hybrid Aptamer for Nanoparticle-Based Prostate Tumor Targeted Drug Delivery.
Leach JC; Wang A; Ye K; Jin S
Int J Mol Sci; 2016 Mar; 17(3):380. PubMed ID: 26985893
[TBL] [Abstract][Full Text] [Related]
8. Polymeric nanoparticles for drug delivery.
Chan JM; Valencia PM; Zhang L; Langer R; Farokhzad OC
Methods Mol Biol; 2010; 624():163-75. PubMed ID: 20217595
[TBL] [Abstract][Full Text] [Related]
9.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
10. A ROS-responsive polymeric prodrug nanosystem with self-amplified drug release for PSMA (-) prostate cancer specific therapy.
Wang Y; Zhang Y; Ru Z; Song W; Chen L; Ma H; Sun L
J Nanobiotechnology; 2019 Aug; 17(1):91. PubMed ID: 31451114
[TBL] [Abstract][Full Text] [Related]
11. Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Saniee F; Shabani Ravari N; Goodarzi N; Amini M; Atyabi F; Saeedian Moghadam E; Dinarvand R
Pharm Dev Technol; 2021 Apr; 26(4):381-389. PubMed ID: 33538232
[TBL] [Abstract][Full Text] [Related]
12. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery.
Cheng J; Teply BA; Sherifi I; Sung J; Luther G; Gu FX; Levy-Nissenbaum E; Radovic-Moreno AF; Langer R; Farokhzad OC
Biomaterials; 2007 Feb; 28(5):869-76. PubMed ID: 17055572
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-mediated nanobubble destruction (UMND) facilitates the delivery of A10-3.2 aptamer targeted and siRNA-loaded cationic nanobubbles for therapy of prostate cancer.
Wu M; Zhao H; Guo L; Wang Y; Song J; Zhao X; Li C; Hao L; Wang D; Tang J
Drug Deliv; 2018 Nov; 25(1):226-240. PubMed ID: 29313393
[TBL] [Abstract][Full Text] [Related]
14. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
[TBL] [Abstract][Full Text] [Related]
15. Prostate-targeted biodegradable nanoparticles loaded with androgen receptor silencing constructs eradicate xenograft tumors in mice.
Yang J; Xie SX; Huang Y; Ling M; Liu J; Ran Y; Wang Y; Thrasher JB; Berkland C; Li B
Nanomedicine (Lond); 2012 Sep; 7(9):1297-309. PubMed ID: 22583574
[TBL] [Abstract][Full Text] [Related]
16. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells.
Farokhzad OC; Jon S; Khademhosseini A; Tran TN; Lavan DA; Langer R
Cancer Res; 2004 Nov; 64(21):7668-72. PubMed ID: 15520166
[TBL] [Abstract][Full Text] [Related]
17. Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers.
Min K; Jo H; Song K; Cho M; Chun YS; Jon S; Kim WJ; Ban C
Biomaterials; 2011 Mar; 32(8):2124-32. PubMed ID: 21147500
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of prostate cancer using anti-PSMA aptamer A10-3.2-oriented lipid nanobubbles.
Fan X; Guo Y; Wang L; Xiong X; Zhu L; Fang K
Int J Nanomedicine; 2016; 11():3939-50. PubMed ID: 27574424
[TBL] [Abstract][Full Text] [Related]
19. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers.
Gu F; Zhang L; Teply BA; Mann N; Wang A; Radovic-Moreno AF; Langer R; Farokhzad OC
Proc Natl Acad Sci U S A; 2008 Feb; 105(7):2586-91. PubMed ID: 18272481
[TBL] [Abstract][Full Text] [Related]
20. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]